Date: 2015-06-22
Type of information: Nomination
Compound:
Company: Intercept Pharmaceuticals (USA - NY)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 22, 2015, Intercept Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases, such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH), announced the appointment of Juan Carlos Lopez-Talavera , M.D., Ph.D. as Senior Vice President of Medical Affairs. Dr. Lopez-Talavera most recently served as Head of Hepatology R&D and Vice President of Medical Affairs at Abbvie, where he was responsible for all Medical Affairs activities supporting the global launch of Abbvie\'s regimen for the treatment of Hepatitis C. Before joining Abbvie, he held positions of increasing responsibility at Roche and Bristol-Myers Squibb, as well as academic positions at the Universidad Autonoma de Barcelona , the University of Pittsburgh School of Medicine , and Yale University School of Medicine .
Financial terms:
Latest news:
